PROMIS NEUROSCIENCES INC

lockPrivate Group

ProMIS Neurosciences is working to detect, target and treat the root causes of neurodegenerative diseases using preci……

people90 Members

Group Admins:
Group Mods:
Request Membership

PROMIS NEUROSCIENCES INC

lockPrivate Group

ProMIS Neurosciences is working to detect, target and treat the root causes of neurodegenerative diseases using preci… …

people90 Members

Request Membership
8020 monitor 200 200 png
8020 Admin4 days
Disclaimer

8020Admin started the topic PMN News Alert: Presents at Upcoming Investor Conferences in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences to Present at Upcoming Investor Conferences

TORONTO and CAMBRIDGE, MA, Jan. 25, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it will participate in two upcoming industry conferences: 

  • Eugene Williams, Executive Chairman, will present at NobleCon14 – Noble Capital Markets’ Fourteenth Annual Investor Conference – at the W Hotel, Fort Lauderdale, Florida, on Tuesday January 30th at 9:30 AM, Eastern Standard Time (EST).

A high-definition, video webcast of the presentation will be available the following day on the Company’s web site www.promiseneurosciences.comand on Noble Capital Markets’ website www.nobleconference.com.  The webcast and presentation will be archived on the company’s website and on Noble’s website for 90 days following the event.

  • Dr. Elliot Goldstein, President and CEO, will present at the Fifth Annual Cantech Investment Conference to be held at the Metro Toronto Convention Centre, Toronto Ontario, on Wednesday January 31st at 4:00 PM, EST. 
    Prior to the presentation, Dr. Goldstein will also participate in a biotechnology panel discussion entitled: ‘Challenges and Triumphs: CEOs Managing Canadian Healthcare Companies for Growth’. The panel discussion, moderated by Eden Rahim of Next Edge Capital will be held at 3:00 PM EST.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at: www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 

SOURCE ProMIS Neurosciences Inc.

News Provided by PR Newswire via QuoteMedia

Show more…Hide…


8020 monitor 200 200 png
8020 Admin4 days
Disclaimer

8020Admin started the topic PMN News Alert: Issues White Paper in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Issues White Paper Entitled: “Not All Amyloid Beta Therapeutics Are Created Equal”

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease 
Shows Improved Therapeutic Potency versus other Amyloid Beta-Directed Antibodies

…….

TORONTO and CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’. This is one of a series of commentaries from the ProMIS scientific team offering insight on Alzheimer’s disease (AD) science and the Company’s emerging product portfolio.

This white paper outlines recent scientific progress indicating that soluble, low molecular weight (LMW) toxic amyloid beta (Aß) oligomers, are the ‘true pathogen’ in Alzheimer’s disease. These LMW toxic oligomers typically consist of twelve (dodecamer), four (tetramer) or two (dimer) strands of Aß .   The clinical activity of Aß -directed antibodies seems correlated with their ability to more selectively target toxic oligomers, consistent with the greater therapeutic activity seen in clinical trials with aducanumab (Biogen) compared to bapineuzumab (Pfizer, Johnson & Johnson). Results of studies with soluble brain material from AD patients recently conducted in the laboratory of ProMIS Chief Scientific Officer, Dr. Neil Cashman, indicate that humanized PMN310 shows significantly greater binding than aducanumab (~1.5-2 fold) to the toxic oligomer-enriched LMW fraction of AD brain extract. 

Commenting on the white paper, Dr. Johanne Kaplan, ProMIS Chief Development Officer, stated: “Recent scientific data indicate that a best in class antibody therapeutic for Alzheimer’s disease should target LMW toxic oligomers without binding Aß  monomers (reduced efficacy) or plaque (increased risk of brain swelling). Preclinical results to date indicate that PMN310 displays such a product profile and has the potential for safe administration of higher effective doses and greater therapeutic potency.” 

The white paper can be accessed directly on the ProMIS Neurosciences website by clicking on the link below:

http://bit.ly/2BqyqTl

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform – ProMIS(TM) and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:
David Schull
RussoPartners/LLC
[email protected]
Tel. 858 717-2310

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
[email protected]

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via Globenewswire
 

News Provided by Thomson Reuters ONE via QuoteMedia

Show more…Hide…


8020 monitor 200 200 png
8020 Admin6 days
Disclaimer

8020Admin started the topic PMN News Alert: Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies

Humanized PMN310 Shows Significantly Greater Binding to The Toxic Oligomer Fraction of Alzheimer’s Disease Brain Extract Compared to Aducanumab

TORONTO and CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced further results of its previously announced and ongoing preclinical program for Alzheimer’s disease (AD). ProMIS is pleased to announce that its lead product candidate for AD, PMN310, compared to aducanumab (Biogen) showed significantly greater binding to the neurotoxic oligomer-enriched fraction of amyloid beta (Abeta) in brain extract from eight confirmed AD brains.

Commenting on these results, ProMIS Executive Chairman, Eugene Williams, stated: “We set out to design an improved antibody inspired by the initial successful clinical results of aducanumab, announced in Dec 2014. We recently reported greater selectivity of PMN310 for Abeta oligomers in direct comparison to other amyloid beta-directed antibodies, including aducanumab. ProMIS also recently announced that PMN310 shows a lack of binding to plaque in and around blood vessels in the brain, thereby supporting the potential for lower risk of brain swelling and possibility of higher dosing with PMN310.”

Williams continued, “We are pleased to announce further results supportive of a best in class profile for our lead AD program.  In comparison to aducanumab, humanized PMN310 showed significantly greater binding to brain material from AD patients containing toxic Abeta oligomers, the root cause of disease. Affinity maturation of PMN310 is ongoing and may result in an even greater advantage with PMN310; we look forward to sharing these results in the coming months.”

Recent reports from the scientific literature1-5 indicate that small, low molecular weight Abeta oligomers, consisting of twelve strands of Abeta (dodecamers), four strands (tetramers) or two strands (dimers) of Abeta are the toxic oligomer form. To test the binding to these toxic oligomers by PMN310 and other Abeta-directed antibodies, ProMIS isolated the soluble low molecular weight (LMW) fraction of brain material from eight AD brains expected to contain dodecamers, tetramers and dimers. Binding by aducanumab, bapineuzumab and humanized PMN310 to the toxic oligomer fraction from these brains was assessed by surface plasmon resonance (SPR). The results showed greater binding of aducanumab to the toxic oligomer LMW fraction compared to bapineuzumab, in line with the greater therapeutic benefit of aducanumab.  Importantly, PMN310 showed even greater binding (~1.5-2 fold) compared to aducanumab. The ability to selectively target LMW toxic Abeta oligomers without binding Abeta monomers (reduced efficacy) or plaque (increased risk of brain swelling, also called ARIA-E) is expected to allow for safe administration of higher effective doses and greater therapeutic potency.

SPR is a highly sensitive technique to detect binding interactions. In the SPR study outlined above, the test antibody therapeutics (bapineuzumab, aducanumab and humanized PMN310) were each immobilized on an SPR sensor chip. The AD brain extract containing the LMW toxic oligomers was then flowed over each of the chips and the amount of toxic oligomer extract bound by the test antibodies was measured.

Additional information can be found in the latest company slide presentation at www.promisneurosciences.com

References

  1. Shankar, GM et al (2008) Amyloid- protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory.  Nat Med 14: 837-842
  2. Jin, M et al (2011) Soluble amyloid -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. PNAS 108: 5819-5834
  3. Cleary, JP et al (2005) Natural oligomers of the amyloid- protein specifically disrupt cognitive function.  Nature Neuroscience 8: 79-84
  4. Yang, T et al (2017) Large soluble oligomers of amyloid -protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate.  J Neurosc 37: 152-163
  5. Lesne, SE et al (2013) Brain amyloid- oligomers in ageing and Alzheimer’s disease. Brain 136: 1383-1398.              

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:
David Schull
Russo Partners/LLC
[email protected]
Tel. 858 717-2310

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
[email protected]

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via Globenewswire
 

News Provided by Thomson Reuters ONE via QuoteMedia

Show more…Hide…


Trevor Shaw7 days

Trevor Shaw has joined the group PROMIS NEUROSCIENCES INC



8020 monitor 200 200 png
8020 Admin7 days
Disclaimer

8020Admin started the topic PMN News Alert: Issues Response to Recent Market Activity in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Issues Response to Recent Market Activity

Canada NewsWire

TORONTO and CAMBRIDGE, MA, Jan. 22, 2017

TORONTO and CAMBRIDGE, MA, Jan. 22, 2017 /CNW/ – At the request of IIROC (“Investment Industry Regulatory Organization of Canada“), ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”) wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.

About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 

SOURCE ProMIS Neurosciences Inc.

 

View original content with multimedia: http://www.newswire.ca/en/releases/archive/January2018/22/c2369.html

For media inquiries, please contact: David Schull, RussoPartners/LLC, [email protected], Tel. 858 717-2310; For Investor Relations please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, [email protected], Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, [email protected] CNW Group 2018

News Provided by Canada Newswire via QuoteMedia

Show more…Hide…


Peter kendall pic
PKen10 days
Disclaimer

PKen commented on update in the group PROMIS NEUROSCIENCES INC

I was wondering if the company had an update or comments about the positive upswing in the markets lately? Anxiously awaiting your response. PKen

Show more…Hide…

We cannot speculate on what drives the markets, but would like to think that our message is getting out: that we are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com.
Peter kendall pic
Thank you for your response Kristen. I understand re: driving the markets just thought I’d ask. I remain very interested in all the progress which ProMIS has made and remain eager for any other updates. I will take a look at the presentation on your site. Enjoy the weekend. PKen

Kristen Galfetti10 days
Disclaimer

Kristen Galfetti commented on update in the group PROMIS NEUROSCIENCES INC

What were your interpretations of the news this week from Lunbeck and the failure of idalopirdine?

http://www.latimes.com/science/sciencenow/la-sci-sn-alzheimers-drug-fail-20180109-story.html

La sci sn alzheimers drug fail 20180109

One of the most promising drugs for Alzheimer's disease fails in clinical trials

To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer’s disease and come up short, we can now add three more.

Show more…Hide…

Our approach to treating Alzheimer’s disease is completely different. Their drug acts to increase the supply of serotonin. We are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com

Kristen Galfetti10 days
Disclaimer

Kristen Galfetti commented on update in the group PROMIS NEUROSCIENCES INC

I was wondering if the company had an update or comments about the positive upswing in the markets lately? Anxiously awaiting your response. PKen

Show more…Hide…

We cannot speculate on what drives the markets, but would like to think that our message is getting out: that we are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com.
Peter kendall pic
Thank you for your response Kristen. I understand re: driving the markets just thought I’d ask. I remain very interested in all the progress which ProMIS has made and remain eager for any other updates. I will take a look at the presentation on your site. Enjoy the weekend. PKen

Peter kendall pic
PKen10 days
Disclaimer

PKen posted an update in the group PROMIS NEUROSCIENCES INC

I was wondering if the company had an update or comments about the positive upswing in the markets lately? Anxiously awaiting your response. PKen

Show more…Hide…

We cannot speculate on what drives the markets, but would like to think that our message is getting out: that we are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com.
Peter kendall pic
Thank you for your response Kristen. I understand re: driving the markets just thought I’d ask. I remain very interested in all the progress which ProMIS has made and remain eager for any other updates. I will take a look at the presentation on your site. Enjoy the weekend. PKen

8020 media relations
Media Relations13 days
Disclaimer

Media Relations posted an update in the group PROMIS NEUROSCIENCES INC

More news in Alzheimer's research today. With a new case diagnosed every 3.2 seconds and the number of people living with the disease expected to double every 20 years, timing seems more critical than ever.

http://www.nydailynews.com/life-style/anxiety-early-indicator-alzheimer-disease-article-1.3758350

521815364

Anxiety could be an early indicator of Alzheimer's disease

Anxiety symptoms could be a warning sign of Alzheimer's disease years before any symptoms of impairment are noticed, a new study found

Show more…Hide…


Peter kendall pic
PKen14 days

PKen has joined the group PROMIS NEUROSCIENCES INC



hjkoot19 days
Disclaimer

hjkoot posted an update in the group PROMIS NEUROSCIENCES INC

What were your interpretations of the news this week from Lunbeck and the failure of idalopirdine?

http://www.latimes.com/science/sciencenow/la-sci-sn-alzheimers-drug-fail-20180109-story.html

La sci sn alzheimers drug fail 20180109

One of the most promising drugs for Alzheimer's disease fails in clinical trials

To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer’s disease and come up short, we can now add three more.

Show more…Hide…

Our approach to treating Alzheimer’s disease is completely different. Their drug acts to increase the supply of serotonin. We are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com

8020 monitor 200 200 png
8020 Admin25 days
Disclaimer

8020Admin started the topic PMN News Alert: Lead Product Candidate for Alzheimer's Disease, PMN310 in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies

Lack of PMN310 binding to perivascular amyloid plaque in Alzheimer’s brain tissue may eliminate dose-limiting brain swelling seen with aducanumab

TORONTO and CAMBRIDGE, Mass., Jan.  04, 2018  (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease (AD), PMN310, showed absence of binding to amyloid beta (Abeta) plaque in and around blood vessels in AD brain samples in a preclinical study directly comparing PMN310 to other Abeta-directed antibodies. Binding of therapeutic antibodies to Abeta deposits in brain tissue, in particular blood vessels, is believed to underlie the development of ARIA (amyloid-related imaging abnormalities; brain swelling and microhemorrhages) in treated AD patients.

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “PMN310 was designed to selectively target the toxic, prion-like Abeta oligomers, now widely believed to be a root cause of AD. By not targeting Abeta plaque, especially in and around blood vessels in the brain, we anticipate PMN310 may not be associated with the dose-limiting brain swelling seen with plaque-binding antibody therapeutics like aducanumab. Confirmation of such an improved safety profile in clinical trials would allow for administration of higher doses to AD patients, thereby leading to greater therapeutic potency of PMN310.”

The binding profile of PMN310 in human AD brain tissue, as well as in brain samples from a mouse AD model, was directly compared to that of other Abeta-directed antibodies in a preclinical study using the technique of immunohistochemistry (IHC). Results of the study showed binding of aducanumab and bapineuzumab to Abeta plaque throughout the brain tissue, including in and around the blood vessels. Conversely, binding of PMN310 to Abeta plaque was not observed in any region of the AD brain tissues.

Prior clinical studies have shown that treatment with antibodies targeting Abeta plaque, like bapineuzumab (Johnson & Johnson) and aducanumab (Biogen), are associated with dose-limiting brain swelling and/or microhemorrhages in a significant number of AD patients. Aducanumab appears to target both Abeta plaque and toxic prion-like Abeta oligomers, the latter now considered by many experts in the field to be the key therapeutic target. We have shown in multiple preclinical studies that PMN310 has the advantage of selectively targeting toxic prion-like Abeta oligomers, with no “off-target” binding to Abeta plaque, potentially allowing for the safe administration of higher effective doses of PMN310 compared to aducanumab.

Immunohistochemistry is the process of selectively imaging antigens (e.g. proteins) in cells of a tissue section by exploiting the principle of antibodies (such as PMN310, aducanumab) binding specifically to their antigen targets in biological tissues. In the study referred to above, IHC was used to assess binding of Abeta-directed antibodies to Abeta plaque in AD brain tissue.

About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
[email protected]
Tel. 718 344-5843

David Schull
RussoPartners/LLC
[email protected]
Tel. 858 717-2310

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
[email protected]

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via Globenewswire
 

News Provided by Thomson Reuters ONE via QuoteMedia

Show more…Hide…


Jim Munro26 days

Jim Munro has joined the group PROMIS NEUROSCIENCES INC



hjkoot27 days
Disclaimer

hjkoot posted an update in the group PROMIS NEUROSCIENCES INC

Forbes thinks biotec is one of the last great growth frontiers for retail investors. If that's true, what differentiates all the players? For ProMIS it's "best in class" therapies, a clear roadmap for success, and a proprietary discovery platform. What do you all think?

https://www.forbes.com/sites/johnjacobs/2015/03/04/biotechnology-one-of-the-last-great-growth-frontiers-for-retail-investors/#774239f576c1

Https%3a%2f%2fblogs images.forbes.com%2fjohnjacobs%2ffiles%2f2015%2f03%2fbiotech 1940x1298

Biotechnology: One of the Last Great Growth Frontiers for Retail Investors

In 1986, Microsoft (NASDAQ: MSFT) went public at a valuation of about $500 million. If you were fortunate enough to invest $10,000 in Microsoft on the first day of trading at $28/share (Microsoft’s stock price closed at $27.75 that day), your shares would be worth nearly $7 million today after […]

Show more…Hide…


Photo
Jonathan Kurtz27 days

Jonathan Kurtz has joined the group PROMIS NEUROSCIENCES INC



No photo
akin.networkhd27 days

akin.networkhd has joined the group PROMIS NEUROSCIENCES INC



No photo
Declan H1 month

Declan H has joined the group PROMIS NEUROSCIENCES INC



No photo
lenhud1 month

lenhud has joined the group PROMIS NEUROSCIENCES INC



No photo
Alex McLean2 months

Alex McLean has joined the group PROMIS NEUROSCIENCES INC



Adam Skibinski2 months

Adam Skibinski has joined the group PROMIS NEUROSCIENCES INC



No photo
Mike Rix2 months

Mike Rix has joined the group PROMIS NEUROSCIENCES INC



8020 media relations
Media Relations2 months
Disclaimer

Media Relations started the topic News Alert: Announces Trading on OTCQB Venture Market in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Announces Trading on OTCQB Venture Market

                                                                                                         

TORONTO, Ontario and CAMBRIDGE, Massachusetts, December 4, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQB® Venture Market (OTCQB) in the United States under the symbol “ARFXF”. OTCQB is a U.S. trading platform operated by the OTC Markets Group in New York.  ProMIS Neurosciences common shares will continue to trade on the Toronto Stock Exchange (TSX:PMN).

“We are pleased to announce our new trading relationship with the OTCQB.  As part of our ongoing strategy to introduce ProMIS to a broader international audience, this milestone will provide greater visibility, better access to the U.S. investment community, and improved convenience of trading the Company’s common shares,” said Elliot Goldstein, M.D., ProMIS President and CEO.

The OTCQB Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting, pass a minimum $0.01 bid price test and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotech company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn

 

For media inquiries, please contact:

Scott Santiamo

RussoPartners/LLC

[email protected]

Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

[email protected]

Tel. 858 717-2310

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

[email protected]

Tel. 617 901-0785

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

[email protected]

 

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation, relating to the commencement of trading of the common shares and warrants of the Company and the composition of the Company’s board of directors following the Meeting. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include, but are not limited to, the Company’s inability to secure shareholder approval required to approve the matters to come before shareholders at the Meeting.

 

Show more…Hide…


8020 monitor 200 200 png
8020Admin2 months
Disclaimer

8020Admin posted an update in the group PROMIS NEUROSCIENCES INC

High incidence of dementia in the UK.

http://www.telegraph.co.uk/science/2017/11/07/dementia-now-britains-biggest-killer-overtaking-heart-disease/?WT.mc_id=tmg_share_em

Dementia 2388492b xlarge trans nvbqzqnjv4bqpjliwavx4cowfcaekesb3kvxit lggwcwqwla rxju8

Dementia now Britain’s biggest killer, overtaking heart disease for first time

Dementia is now Britain’s biggest killer, overtaking heart disease for first time new figures have shown.

Show more…Hide…


8020 monitor 200 200 png
8020Admin2 months
Disclaimer

8020Admin posted an update in the group PROMIS NEUROSCIENCES INC

Westwood One Radio Interview with Dr. Elliot Goldstein

https://promisneurosciences.com/in-the-news/westwood-one-radio-alzheimers-disease/

Promislogo3

Westwood One Radio: Alzheimer's Disease – ProMIS Neurosciences

ProMIS™ Neurosciences, Inc., is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

Show more…Hide…


No photo
Laura ZHU2 months

Laura ZHU has joined the group PROMIS NEUROSCIENCES INC



Dave St-Germain2 months

Dave St-Germain has joined the group PROMIS NEUROSCIENCES INC



8020 monitor 200 200 png
8020 Admin3 months
Disclaimer

8020Admin started the topic PMN News Alert: Announces Third Quarter 2017 Results in group PROMIS NEUROSCIENCES INC

ProMISTM Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN

FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences Announces Third Quarter 2017 Results

 

TORONTO, Ontario and CAMBRIDGE, Massachusetts November 13, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2017.

 

Commenting on the update, Elliot Goldstein, M.D., ProMIS President and CEO stated: “With the successful private placement in Q3 2017 supporting a cash runway into the second half of 2018, we continue to focus on the company’s top priorities.  In this regard, we look forward to further advancing the development of our lead product candidates for Alzheimer’s disease with particular emphasis on the ongoing preclinical program to differentiate our leads compared to competitive antibody products in development. We remain confident that our monoclonal antibody program focused on selectively targeting the toxic, prion-like forms of amyloid beta may lead to best in class therapies and significant long-term value creation.”

 

 

Recent Corporate Highlights

 

·      In August 2017, the Company completed a brokered private placement offering (the Offering) through the issuance of 19,164,306 units at a price of $0.25 per unit for gross proceeds of $4,791,076 ($4,142,465 net of issuance costs). Each Unit consists of one common share and one-half of a common share purchase warrant.  The issued common shares are subject to a four-month hold period from the date of issuance.  Each whole warrant is exercisable into one share at a price of $0.30 per share for a 60-month exercise period.

 

·      On September 13, 2017, the Company announced a significant development milestone by demonstrating that PMN330, directed against a different target on toxic amyloid beta oligomers (AbO) compared to PMN310 and PMN350, also displays an optimal target product profile of selective binding to toxic AbO. PMN330 was designated third validated lead product candidate having demonstrated in vivo data and biologic evidence of neuronal protection against toxic AbO.

 

·      In Q3 2017 the Company initiated its preclinical program to evaluate the potential best in class profile of PMN310, PMN350 and PMN330 in direct comparison to other antibodies targeting amyloid beta.

 

·      In Q3 the Company generated monoclonal antibodies against a recently identified epitope target on TDP43 for ALS and frontotemporal dementia and initiated preclinical evaluation.

·      Using the ProMIS proprietary discovery platform the Company is pursuing identification of specific targets on alpha synuclein (Parkinson’s disease and Lewy body dementia) and tau (Alzheimer’s disease, other dementias).

 

Financial Results

Results of Operations – Three months ended September 30, 2017 and 2016

The net loss for the three months ended September 30, 2017 was $1,618,681, compared to a net loss of $859,371 for the three months ended September 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.  

For the three months ended September 30, 2017, the Company recognized $9,008 in royalty revenue related to its preclinical AD diagnostic assay as compared to $0 for the three months ended September 30, 2016.

Research and development expenses for the three months ended September 30, 2017 were $1,317,893 as compared to $492,717 in the three months ended September 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program and increased headcount. 

General and administrative expenses for the three months ended September 30, 2017 were $307,533 as compared to $366,654 in the three months ended June 30, 2016.  The decreased expenditures in the current period reflect Foreign exchange gain on USD denominated expenses and decreased legal and professional fees, offset by higher investor relations expenses and higher salaries related to expansion of the senior management team. 

Results of Operations – Nine months ended September 30, 2017 and 2016

The net loss for the nine months ended September 30, 2017 was $4,894,280, compared to a net loss of $2,243,874 for the nine months ended June 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.  

For the nine months ended September 30, 2017, the Company recognized $9,666 in royalty revenue related to its preclinical AD diagnostic assay as compared to $2,486 for the nine months ended September 30, 2016.

Research and development expenses for the nine months ended September 30, 2017 were $3,303,962 as compared to $1,169,228 in the nine months ended September 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program, supporting its patent portfolio and increased headcount 

General and administrative expenses for the nine months ended September 30, 2017 were $1,592,881 as compared to $1,063,710 in the nine months ended September30, 2016.  The increased expenditures in the current period reflect higher investor relations expenses, higher salaries related to expansion of the senior management team, higher professional fees, and higher stock-based compensation offset by foreign exchange gain on USD denominated expense and reduced legal expenses. 

 

Outlook

The Company’s priorities for the next year are to identify and develop precision medicine therapeutics for Alzheimer’s disease (AD) and ALS.

The Company’s plan is to further advance its AD portfolio, with a focus on competitive differentiation versus other antibody therapies in development for AD that target amyloid beta. Furthermore, the Company plans to continue on-going development of effective AD diagnostics for detection of toxic prion strains targeted by ProMIS antibody therapeutic candidates in either cerebrospinal fluid or blood. Technology refinement and optimization are ongoing to create highly sensitive assays for this purpose.

The Company will continue to expand its intellectual property estate relating to novel epitope targets and antibodies targeting toxic forms of tau for AD, misfolded forms of  TDP43 for ALS and  toxic strains of alpha synuclein for Parkinson’s disease. The Company’s complementary proprietary platform technologies, ProMISTM and Collective Coordinates, will be employed to identify and confirm such novel targets.

 

About ProMIS Neurosciences, Inc.

 

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The Company’s   proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

For further information please consult the Company’s website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn

 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
[email protected]
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

[email protected]

Tel. 858 717-2310

 

For Investor Relations please contact:

 

Alpine Equity Advisors

Nicholas Rigopulos, President

[email protected]

Tel. 617 901-0785

 

 

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

[email protected]

 

 

 

 

 

Show more…Hide…


hjkoot3 months

hjkoot has joined the group PROMIS NEUROSCIENCES INC



Victoria Bennett3 months

Victoria Bennett has joined the group PROMIS NEUROSCIENCES INC



Kristen Galfetti3 months

Kristen Galfetti has joined the group PROMIS NEUROSCIENCES INC



No photo
Sally Woo3 months

Sally Woo has joined the group PROMIS NEUROSCIENCES INC



8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic WHY IS PROMIS NEUROSCIENCE A GOOD INVESTMENT? POINT 2. in group PROMIS NEUROSCIENCES INC

 2. Management team. Experienced, complementary management team with outstanding scientific and business advisory boards.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic Why is ProMis Neuroscience a good investment? Point 1. in group PROMIS NEUROSCIENCES INC

  1. Massive market opportunity and unmet medical need in Alzheimer’s disease. No therapies available today to stop the progression of Alzheimer’s disease (AD). Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years. ProMIS product candidates are uniquely designed to selectively block the toxic strains of Amyloid beta, to stop the fundamental, underlying driver causing death of brain neurons in AD.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations posted an update in the group PROMIS NEUROSCIENCES INC

Please note the recent coverage of PMN310 by Alzheimer’s News today.

https://alzheimersnewstoday.com/2017/10/20/study-shows-that-alzheimers-therapy-pmn310-binds-only-to-toxic-amyloid-beta/

Shutterstock 256201054

Alzheimer's Therapy PMN310 Binds Only to Toxic Protein, Study Shows

Read about a study showing that ProMIS's antibody therapy PMN310 binds only with the harmful forms of amyloid beta associated with Alzheimer’s.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic Presentation by ProMIS Chief Development Officer, Dr. Johanne Kaplan, on PMN310 Best in Class Product Profile in group PROMIS NEUROSCIENCES INC

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic $PMN: News Alert Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in group PROMIS NEUROSCIENCES INC

 ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease

Narrated presentation of results available on ProMIS website

TSX: PMN

TORONTO and CAMBRIDGE, MA, Oct. 17, 2017 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer’s disease (AD).

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

A narrated presentation of these results is available on the ProMIS Neurosciences website at: http://bit.ly/2gp8S4t

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “We are pleased to confirm the selective binding of PMN310 to amyloid beta oligomers, a root cause of Alzheimer’s disease. Results of prior clinical studies with other amyloid beta antibody therapeutics clearly showed that antibodies targeting amyloid beta monomer have consistently been ineffective, while those targeting amyloid beta fibrils, the main component of plaque, are associated with a dose limiting toxicity of brain swelling. Taken together, results of prior clinical trials indicate the best in class target product profile is selective binding of toxic amyloid beta oligomers.”

The binding profile of PMN310 was compared to that of other candidate antibody therapeutics for AD in a preclinical study using the “dot blot” technique. Results of the study showed that PMN310 selectively binds amyloid beta oligomers (AbO), with virtually no binding to the other forms of amyloid beta. By comparison, solanezumab (Eli Lilly) showed binding mainly to Ab monomers; bapineuzumab (Johnson & Johnson/Pfizer, discontinued) showed binding to all forms of Ab (monomers, fibrils, oligomers); and aducanumab (Biogen) showed preferential binding to fibrils and oligomers.

Dot blotting is a method of applying (dotting) proteins, such as Ab monomers, fibrils and oligomers, directly onto a membrane or other support. Samples of the antibody to be evaluated are then applied and the binding pattern to the various forms of amyloid beta can be observed.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company’s website at: 
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

 

SOURCE ProMIS Neurosciences Inc.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations posted an update in the group PROMIS NEUROSCIENCES INC

Narrated Corporate Overview October 2017

Show more…Hide…


Elliot Goldstein4 months

Elliot Goldstein has joined the group PROMIS NEUROSCIENCES INC



Darren Stewart4 months
Disclaimer

Darren Stewart posted an update in the group PROMIS NEUROSCIENCES INC

I want to bring your attention to a new tool we added in September, the "New User" invite tool. It's very simple, just add the email of a person you think would be an interested investor or could add value to the corporation. Click on the "SEND INVITES" button above to find the New User tool. (The image below should help). As shareholders, we now have the ability to be more than passive investors, we can be active owners helping our investments succeed. Darren Stewart, CEO and founder of 8020 Connect.

Show more…Hide…


Yousuf Soliman4 months

Yousuf Soliman has joined the group PROMIS NEUROSCIENCES INC



8020 media relations
Media Relations4 months
Disclaimer

Media Relations started the topic $PMN News Alert: ProMIS Neurosciences Provides Third Quarter Update for 2017 in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Provides Third Quarter Update for 2017

Updated corporate overview available on ProMIS website

TSX: PMN

TORONTO and CAMBRIDGE, MA, Oct. 11, 2017 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the third quarter of 2017, including key accomplishments and a status update on ongoing programs.

A narrated corporate overview of third quarter 2017 progress is available on the ProMIS Neurosciences website at: http://bit.ly/2xuss6Q

 Key accomplishments in the third quarter of 2017 and near-term value drivers include:

  • Closed second and final tranche of private placement, raising aggregate gross proceeds of approximately CDN $4,800,000
  • Successful humanization of lead product candidate PMN310 for Alzheimer’s disease 
    • PMN310 on track for 2019 initiation of clinical trials
  • Expansion of potential best in class portfolio selectively targeting toxic Amyloid beta oligomers (AβO) for Alzheimer’s disease
    • Designated PMN330 as third validated lead product candidate demonstrating in vivo data and biologic evidence of neuronal protection against toxic AβO
    • Initiated humanization of PMN330 and PMN350
  • Preclinical program initiated to confirm best in class profile of PMN310, PMN350 and PMN330 in direct comparison to other antibodies targeting amyloid beta
  • Cohort study progress
    • Technology refinement and optimization ongoing to create highly sensitive assays for detection of AβO targets in cerebrospinal fluid (CSF)
  • Recognition and visibility at major international meetings
    • Oral presentation and session chair at Alzheimer’s Association International Conference, London, UK, July, 2017
    • Oral presentation at Third Annual R&D Technologies Conference, London, UK, September, 2017
  • Progress relating to multiple neurodegenerative diseases
    • Generated monoclonal antibodies against a recently identified epitope target on TDP43 for ALS and frontotemporal dementia and initiated preclinical evaluation.
    • Ongoing work using ProMIS proprietary discovery platform to identify specific targets on alpha synuclein (Parkinson’s disease and Lewy body dementia) and tau (Alzheimer’s disease, other dementias)

 

Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: “Our Alzheimer’s disease program continues to make significant progress. With respect to drug development, our priorities for this program are twofold: to drive PMN310 to clinical trial initiation in 2019 and importantly, to further differentiate our Alzheimer’s product candidates as best in class in direct comparison to other antibody treatments targeting Amyloid beta. With respect to our research programs, we are pleased with the progress made using our proprietary discovery engine to identify novel targets for multiple neurodegenerative diseases.”

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Show more…Hide…


LauraGaret4 months
Disclaimer

LauraGaret posted an update in the group PROMIS NEUROSCIENCES INC

https://www.wired.com/story/polygenic-alzheimers-test-predicts-age-of-disease-onset/

Alzheimers fa

This New Alzheimer’s Test Looks Beyond a Single Problem Gene

It calculates how more than two dozen genetic variants combine to increase or decrease your risk of developing Alzheimer's during your lifetime.

Show more…Hide…


PROMIS NEUROSCIENCES INC

lockPrivate Group

ProMIS Neurosciences is working to detect, target and treat the root causes of neurodegenerative diseases using preci……

people90 Members

Request Membership

PROMIS NEUROSCIENCES INC

lockPrivate Group

ProMIS Neurosciences is working to detect, target and treat the root causes of neurodegenerative diseases using preci… …

people90 Members

Request Membership
8020 monitor 200 200 png
8020 Admin4 days
Disclaimer

8020Admin started the topic PMN News Alert: Presents at Upcoming Investor Conferences in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences to Present at Upcoming Investor Conferences

TORONTO and CAMBRIDGE, MA, Jan. 25, 2018 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that it will participate in two upcoming industry conferences: 

  • Eugene Williams, Executive Chairman, will present at NobleCon14 – Noble Capital Markets’ Fourteenth Annual Investor Conference – at the W Hotel, Fort Lauderdale, Florida, on Tuesday January 30th at 9:30 AM, Eastern Standard Time (EST).

A high-definition, video webcast of the presentation will be available the following day on the Company’s web site www.promiseneurosciences.comand on Noble Capital Markets’ website www.nobleconference.com.  The webcast and presentation will be archived on the company’s website and on Noble’s website for 90 days following the event.

  • Dr. Elliot Goldstein, President and CEO, will present at the Fifth Annual Cantech Investment Conference to be held at the Metro Toronto Convention Centre, Toronto Ontario, on Wednesday January 31st at 4:00 PM, EST. 
    Prior to the presentation, Dr. Goldstein will also participate in a biotechnology panel discussion entitled: ‘Challenges and Triumphs: CEOs Managing Canadian Healthcare Companies for Growth’. The panel discussion, moderated by Eden Rahim of Next Edge Capital will be held at 3:00 PM EST.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at: www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 

SOURCE ProMIS Neurosciences Inc.

News Provided by PR Newswire via QuoteMedia

Show more…Hide…


8020 monitor 200 200 png
8020 Admin4 days
Disclaimer

8020Admin started the topic PMN News Alert: Issues White Paper in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Issues White Paper Entitled: “Not All Amyloid Beta Therapeutics Are Created Equal”

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease 
Shows Improved Therapeutic Potency versus other Amyloid Beta-Directed Antibodies

…….

TORONTO and CAMBRIDGE, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’. This is one of a series of commentaries from the ProMIS scientific team offering insight on Alzheimer’s disease (AD) science and the Company’s emerging product portfolio.

This white paper outlines recent scientific progress indicating that soluble, low molecular weight (LMW) toxic amyloid beta (Aß) oligomers, are the ‘true pathogen’ in Alzheimer’s disease. These LMW toxic oligomers typically consist of twelve (dodecamer), four (tetramer) or two (dimer) strands of Aß .   The clinical activity of Aß -directed antibodies seems correlated with their ability to more selectively target toxic oligomers, consistent with the greater therapeutic activity seen in clinical trials with aducanumab (Biogen) compared to bapineuzumab (Pfizer, Johnson & Johnson). Results of studies with soluble brain material from AD patients recently conducted in the laboratory of ProMIS Chief Scientific Officer, Dr. Neil Cashman, indicate that humanized PMN310 shows significantly greater binding than aducanumab (~1.5-2 fold) to the toxic oligomer-enriched LMW fraction of AD brain extract. 

Commenting on the white paper, Dr. Johanne Kaplan, ProMIS Chief Development Officer, stated: “Recent scientific data indicate that a best in class antibody therapeutic for Alzheimer’s disease should target LMW toxic oligomers without binding Aß  monomers (reduced efficacy) or plaque (increased risk of brain swelling). Preclinical results to date indicate that PMN310 displays such a product profile and has the potential for safe administration of higher effective doses and greater therapeutic potency.” 

The white paper can be accessed directly on the ProMIS Neurosciences website by clicking on the link below:

http://bit.ly/2BqyqTl

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform – ProMIS(TM) and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:
David Schull
RussoPartners/LLC
[email protected]
Tel. 858 717-2310

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
[email protected]

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via Globenewswire
 

News Provided by Thomson Reuters ONE via QuoteMedia

Show more…Hide…


8020 monitor 200 200 png
8020 Admin6 days
Disclaimer

8020Admin started the topic PMN News Alert: Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies

Humanized PMN310 Shows Significantly Greater Binding to The Toxic Oligomer Fraction of Alzheimer’s Disease Brain Extract Compared to Aducanumab

TORONTO and CAMBRIDGE, Mass., Jan. 23, 2018 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX:PMN) (OTCQB:ARFXF), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced further results of its previously announced and ongoing preclinical program for Alzheimer’s disease (AD). ProMIS is pleased to announce that its lead product candidate for AD, PMN310, compared to aducanumab (Biogen) showed significantly greater binding to the neurotoxic oligomer-enriched fraction of amyloid beta (Abeta) in brain extract from eight confirmed AD brains.

Commenting on these results, ProMIS Executive Chairman, Eugene Williams, stated: “We set out to design an improved antibody inspired by the initial successful clinical results of aducanumab, announced in Dec 2014. We recently reported greater selectivity of PMN310 for Abeta oligomers in direct comparison to other amyloid beta-directed antibodies, including aducanumab. ProMIS also recently announced that PMN310 shows a lack of binding to plaque in and around blood vessels in the brain, thereby supporting the potential for lower risk of brain swelling and possibility of higher dosing with PMN310.”

Williams continued, “We are pleased to announce further results supportive of a best in class profile for our lead AD program.  In comparison to aducanumab, humanized PMN310 showed significantly greater binding to brain material from AD patients containing toxic Abeta oligomers, the root cause of disease. Affinity maturation of PMN310 is ongoing and may result in an even greater advantage with PMN310; we look forward to sharing these results in the coming months.”

Recent reports from the scientific literature1-5 indicate that small, low molecular weight Abeta oligomers, consisting of twelve strands of Abeta (dodecamers), four strands (tetramers) or two strands (dimers) of Abeta are the toxic oligomer form. To test the binding to these toxic oligomers by PMN310 and other Abeta-directed antibodies, ProMIS isolated the soluble low molecular weight (LMW) fraction of brain material from eight AD brains expected to contain dodecamers, tetramers and dimers. Binding by aducanumab, bapineuzumab and humanized PMN310 to the toxic oligomer fraction from these brains was assessed by surface plasmon resonance (SPR). The results showed greater binding of aducanumab to the toxic oligomer LMW fraction compared to bapineuzumab, in line with the greater therapeutic benefit of aducanumab.  Importantly, PMN310 showed even greater binding (~1.5-2 fold) compared to aducanumab. The ability to selectively target LMW toxic Abeta oligomers without binding Abeta monomers (reduced efficacy) or plaque (increased risk of brain swelling, also called ARIA-E) is expected to allow for safe administration of higher effective doses and greater therapeutic potency.

SPR is a highly sensitive technique to detect binding interactions. In the SPR study outlined above, the test antibody therapeutics (bapineuzumab, aducanumab and humanized PMN310) were each immobilized on an SPR sensor chip. The AD brain extract containing the LMW toxic oligomers was then flowed over each of the chips and the amount of toxic oligomer extract bound by the test antibodies was measured.

Additional information can be found in the latest company slide presentation at www.promisneurosciences.com

References

  1. Shankar, GM et al (2008) Amyloid- protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory.  Nat Med 14: 837-842
  2. Jin, M et al (2011) Soluble amyloid -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. PNAS 108: 5819-5834
  3. Cleary, JP et al (2005) Natural oligomers of the amyloid- protein specifically disrupt cognitive function.  Nature Neuroscience 8: 79-84
  4. Yang, T et al (2017) Large soluble oligomers of amyloid -protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate.  J Neurosc 37: 152-163
  5. Lesne, SE et al (2013) Brain amyloid- oligomers in ageing and Alzheimer’s disease. Brain 136: 1383-1398.              

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:
David Schull
Russo Partners/LLC
[email protected]
Tel. 858 717-2310

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
[email protected]

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via Globenewswire
 

News Provided by Thomson Reuters ONE via QuoteMedia

Show more…Hide…


Trevor Shaw7 days

Trevor Shaw has joined the group PROMIS NEUROSCIENCES INC



8020 monitor 200 200 png
8020 Admin7 days
Disclaimer

8020Admin started the topic PMN News Alert: Issues Response to Recent Market Activity in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Issues Response to Recent Market Activity

Canada NewsWire

TORONTO and CAMBRIDGE, MA, Jan. 22, 2017

TORONTO and CAMBRIDGE, MA, Jan. 22, 2017 /CNW/ – At the request of IIROC (“Investment Industry Regulatory Organization of Canada“), ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”) wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.

About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 

SOURCE ProMIS Neurosciences Inc.

 

View original content with multimedia: http://www.newswire.ca/en/releases/archive/January2018/22/c2369.html

For media inquiries, please contact: David Schull, RussoPartners/LLC, [email protected], Tel. 858 717-2310; For Investor Relations please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, [email protected], Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, [email protected] CNW Group 2018

News Provided by Canada Newswire via QuoteMedia

Show more…Hide…


Peter kendall pic
PKen10 days
Disclaimer

PKen commented on update in the group PROMIS NEUROSCIENCES INC

I was wondering if the company had an update or comments about the positive upswing in the markets lately? Anxiously awaiting your response. PKen

Show more…Hide…

We cannot speculate on what drives the markets, but would like to think that our message is getting out: that we are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com.
Peter kendall pic
Thank you for your response Kristen. I understand re: driving the markets just thought I’d ask. I remain very interested in all the progress which ProMIS has made and remain eager for any other updates. I will take a look at the presentation on your site. Enjoy the weekend. PKen

Kristen Galfetti10 days
Disclaimer

Kristen Galfetti commented on update in the group PROMIS NEUROSCIENCES INC

What were your interpretations of the news this week from Lunbeck and the failure of idalopirdine?

http://www.latimes.com/science/sciencenow/la-sci-sn-alzheimers-drug-fail-20180109-story.html

La sci sn alzheimers drug fail 20180109

One of the most promising drugs for Alzheimer's disease fails in clinical trials

To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer’s disease and come up short, we can now add three more.

Show more…Hide…

Our approach to treating Alzheimer’s disease is completely different. Their drug acts to increase the supply of serotonin. We are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com

Kristen Galfetti10 days
Disclaimer

Kristen Galfetti commented on update in the group PROMIS NEUROSCIENCES INC

I was wondering if the company had an update or comments about the positive upswing in the markets lately? Anxiously awaiting your response. PKen

Show more…Hide…

We cannot speculate on what drives the markets, but would like to think that our message is getting out: that we are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com.
Peter kendall pic
Thank you for your response Kristen. I understand re: driving the markets just thought I’d ask. I remain very interested in all the progress which ProMIS has made and remain eager for any other updates. I will take a look at the presentation on your site. Enjoy the weekend. PKen

Peter kendall pic
PKen10 days
Disclaimer

PKen posted an update in the group PROMIS NEUROSCIENCES INC

I was wondering if the company had an update or comments about the positive upswing in the markets lately? Anxiously awaiting your response. PKen

Show more…Hide…

We cannot speculate on what drives the markets, but would like to think that our message is getting out: that we are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com.
Peter kendall pic
Thank you for your response Kristen. I understand re: driving the markets just thought I’d ask. I remain very interested in all the progress which ProMIS has made and remain eager for any other updates. I will take a look at the presentation on your site. Enjoy the weekend. PKen

8020 media relations
Media Relations13 days
Disclaimer

Media Relations posted an update in the group PROMIS NEUROSCIENCES INC

More news in Alzheimer's research today. With a new case diagnosed every 3.2 seconds and the number of people living with the disease expected to double every 20 years, timing seems more critical than ever.

http://www.nydailynews.com/life-style/anxiety-early-indicator-alzheimer-disease-article-1.3758350

521815364

Anxiety could be an early indicator of Alzheimer's disease

Anxiety symptoms could be a warning sign of Alzheimer's disease years before any symptoms of impairment are noticed, a new study found

Show more…Hide…


Peter kendall pic
PKen14 days

PKen has joined the group PROMIS NEUROSCIENCES INC



hjkoot19 days
Disclaimer

hjkoot posted an update in the group PROMIS NEUROSCIENCES INC

What were your interpretations of the news this week from Lunbeck and the failure of idalopirdine?

http://www.latimes.com/science/sciencenow/la-sci-sn-alzheimers-drug-fail-20180109-story.html

La sci sn alzheimers drug fail 20180109

One of the most promising drugs for Alzheimer's disease fails in clinical trials

To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer’s disease and come up short, we can now add three more.

Show more…Hide…

Our approach to treating Alzheimer’s disease is completely different. Their drug acts to increase the supply of serotonin. We are developing best in class therapies consisting of personalized antibodies designed to selectively target toxic misfolded amyloid beta oligomers, believed to be the root cause Alzheimers disease. Please see our latest presentation on our web site for more details. www.promisneurosciences.com

8020 monitor 200 200 png
8020 Admin25 days
Disclaimer

8020Admin started the topic PMN News Alert: Lead Product Candidate for Alzheimer's Disease, PMN310 in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies

Lack of PMN310 binding to perivascular amyloid plaque in Alzheimer’s brain tissue may eliminate dose-limiting brain swelling seen with aducanumab

TORONTO and CAMBRIDGE, Mass., Jan.  04, 2018  (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease (AD), PMN310, showed absence of binding to amyloid beta (Abeta) plaque in and around blood vessels in AD brain samples in a preclinical study directly comparing PMN310 to other Abeta-directed antibodies. Binding of therapeutic antibodies to Abeta deposits in brain tissue, in particular blood vessels, is believed to underlie the development of ARIA (amyloid-related imaging abnormalities; brain swelling and microhemorrhages) in treated AD patients.

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “PMN310 was designed to selectively target the toxic, prion-like Abeta oligomers, now widely believed to be a root cause of AD. By not targeting Abeta plaque, especially in and around blood vessels in the brain, we anticipate PMN310 may not be associated with the dose-limiting brain swelling seen with plaque-binding antibody therapeutics like aducanumab. Confirmation of such an improved safety profile in clinical trials would allow for administration of higher doses to AD patients, thereby leading to greater therapeutic potency of PMN310.”

The binding profile of PMN310 in human AD brain tissue, as well as in brain samples from a mouse AD model, was directly compared to that of other Abeta-directed antibodies in a preclinical study using the technique of immunohistochemistry (IHC). Results of the study showed binding of aducanumab and bapineuzumab to Abeta plaque throughout the brain tissue, including in and around the blood vessels. Conversely, binding of PMN310 to Abeta plaque was not observed in any region of the AD brain tissues.

Prior clinical studies have shown that treatment with antibodies targeting Abeta plaque, like bapineuzumab (Johnson & Johnson) and aducanumab (Biogen), are associated with dose-limiting brain swelling and/or microhemorrhages in a significant number of AD patients. Aducanumab appears to target both Abeta plaque and toxic prion-like Abeta oligomers, the latter now considered by many experts in the field to be the key therapeutic target. We have shown in multiple preclinical studies that PMN310 has the advantage of selectively targeting toxic prion-like Abeta oligomers, with no “off-target” binding to Abeta plaque, potentially allowing for the safe administration of higher effective doses of PMN310 compared to aducanumab.

Immunohistochemistry is the process of selectively imaging antigens (e.g. proteins) in cells of a tissue section by exploiting the principle of antibodies (such as PMN310, aducanumab) binding specifically to their antigen targets in biological tissues. In the study referred to above, IHC was used to assess binding of Abeta-directed antibodies to Abeta plaque in AD brain tissue.

About ProMIS Neurosciences, Inc.
ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform-ProMIS(TM) and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

For media inquiries, please contact:
Scott Santiamo
RussoPartners/LLC
[email protected]
Tel. 718 344-5843

David Schull
RussoPartners/LLC
[email protected]
Tel. 858 717-2310

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785

Dr. Elliot Goldstein
President and Chief Executive Officer, ProMIS Neurosciences Inc.
Tel. 415 341-5783
[email protected]

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProMIS Neurosciences via Globenewswire
 

News Provided by Thomson Reuters ONE via QuoteMedia

Show more…Hide…


Jim Munro26 days

Jim Munro has joined the group PROMIS NEUROSCIENCES INC



hjkoot27 days
Disclaimer

hjkoot posted an update in the group PROMIS NEUROSCIENCES INC

Forbes thinks biotec is one of the last great growth frontiers for retail investors. If that's true, what differentiates all the players? For ProMIS it's "best in class" therapies, a clear roadmap for success, and a proprietary discovery platform. What do you all think?

https://www.forbes.com/sites/johnjacobs/2015/03/04/biotechnology-one-of-the-last-great-growth-frontiers-for-retail-investors/#774239f576c1

Https%3a%2f%2fblogs images.forbes.com%2fjohnjacobs%2ffiles%2f2015%2f03%2fbiotech 1940x1298

Biotechnology: One of the Last Great Growth Frontiers for Retail Investors

In 1986, Microsoft (NASDAQ: MSFT) went public at a valuation of about $500 million. If you were fortunate enough to invest $10,000 in Microsoft on the first day of trading at $28/share (Microsoft’s stock price closed at $27.75 that day), your shares would be worth nearly $7 million today after […]

Show more…Hide…


Photo
Jonathan Kurtz27 days

Jonathan Kurtz has joined the group PROMIS NEUROSCIENCES INC



No photo
akin.networkhd27 days

akin.networkhd has joined the group PROMIS NEUROSCIENCES INC



No photo
Declan H1 month

Declan H has joined the group PROMIS NEUROSCIENCES INC



No photo
lenhud1 month

lenhud has joined the group PROMIS NEUROSCIENCES INC



No photo
Alex McLean2 months

Alex McLean has joined the group PROMIS NEUROSCIENCES INC



Adam Skibinski2 months

Adam Skibinski has joined the group PROMIS NEUROSCIENCES INC



No photo
Mike Rix2 months

Mike Rix has joined the group PROMIS NEUROSCIENCES INC



8020 media relations
Media Relations2 months
Disclaimer

Media Relations started the topic News Alert: Announces Trading on OTCQB Venture Market in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Announces Trading on OTCQB Venture Market

                                                                                                         

TORONTO, Ontario and CAMBRIDGE, Massachusetts, December 4, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its common shares have been approved for trading on the OTCQB® Venture Market (OTCQB) in the United States under the symbol “ARFXF”. OTCQB is a U.S. trading platform operated by the OTC Markets Group in New York.  ProMIS Neurosciences common shares will continue to trade on the Toronto Stock Exchange (TSX:PMN).

“We are pleased to announce our new trading relationship with the OTCQB.  As part of our ongoing strategy to introduce ProMIS to a broader international audience, this milestone will provide greater visibility, better access to the U.S. investment community, and improved convenience of trading the Company’s common shares,” said Elliot Goldstein, M.D., ProMIS President and CEO.

The OTCQB Venture Market is for early-stage and developing U.S. and international companies. To be eligible, companies must be current in their financial reporting, pass a minimum $0.01 bid price test and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotech company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn

 

For media inquiries, please contact:

Scott Santiamo

RussoPartners/LLC

[email protected]

Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

[email protected]

Tel. 858 717-2310

 

For Investor Relations please contact:

Alpine Equity Advisors

Nicholas Rigopulos, President

[email protected]

Tel. 617 901-0785

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

[email protected]

 

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation, relating to the commencement of trading of the common shares and warrants of the Company and the composition of the Company’s board of directors following the Meeting. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include, but are not limited to, the Company’s inability to secure shareholder approval required to approve the matters to come before shareholders at the Meeting.

 

Show more…Hide…


8020 monitor 200 200 png
8020Admin2 months
Disclaimer

8020Admin posted an update in the group PROMIS NEUROSCIENCES INC

High incidence of dementia in the UK.

http://www.telegraph.co.uk/science/2017/11/07/dementia-now-britains-biggest-killer-overtaking-heart-disease/?WT.mc_id=tmg_share_em

Dementia 2388492b xlarge trans nvbqzqnjv4bqpjliwavx4cowfcaekesb3kvxit lggwcwqwla rxju8

Dementia now Britain’s biggest killer, overtaking heart disease for first time

Dementia is now Britain’s biggest killer, overtaking heart disease for first time new figures have shown.

Show more…Hide…


8020 monitor 200 200 png
8020Admin2 months
Disclaimer

8020Admin posted an update in the group PROMIS NEUROSCIENCES INC

Westwood One Radio Interview with Dr. Elliot Goldstein

https://promisneurosciences.com/in-the-news/westwood-one-radio-alzheimers-disease/

Promislogo3

Westwood One Radio: Alzheimer's Disease – ProMIS Neurosciences

ProMIS™ Neurosciences, Inc., is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

Show more…Hide…


No photo
Laura ZHU2 months

Laura ZHU has joined the group PROMIS NEUROSCIENCES INC



Dave St-Germain2 months

Dave St-Germain has joined the group PROMIS NEUROSCIENCES INC



8020 monitor 200 200 png
8020 Admin3 months
Disclaimer

8020Admin started the topic PMN News Alert: Announces Third Quarter 2017 Results in group PROMIS NEUROSCIENCES INC

ProMISTM Neurosciences, Inc.

 

NEWS RELEASE TSX: PMN

FOR IMMEDIATE RELEASE

 

ProMIS Neurosciences Announces Third Quarter 2017 Results

 

TORONTO, Ontario and CAMBRIDGE, Massachusetts November 13, 2017 – ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2017.

 

Commenting on the update, Elliot Goldstein, M.D., ProMIS President and CEO stated: “With the successful private placement in Q3 2017 supporting a cash runway into the second half of 2018, we continue to focus on the company’s top priorities.  In this regard, we look forward to further advancing the development of our lead product candidates for Alzheimer’s disease with particular emphasis on the ongoing preclinical program to differentiate our leads compared to competitive antibody products in development. We remain confident that our monoclonal antibody program focused on selectively targeting the toxic, prion-like forms of amyloid beta may lead to best in class therapies and significant long-term value creation.”

 

 

Recent Corporate Highlights

 

·      In August 2017, the Company completed a brokered private placement offering (the Offering) through the issuance of 19,164,306 units at a price of $0.25 per unit for gross proceeds of $4,791,076 ($4,142,465 net of issuance costs). Each Unit consists of one common share and one-half of a common share purchase warrant.  The issued common shares are subject to a four-month hold period from the date of issuance.  Each whole warrant is exercisable into one share at a price of $0.30 per share for a 60-month exercise period.

 

·      On September 13, 2017, the Company announced a significant development milestone by demonstrating that PMN330, directed against a different target on toxic amyloid beta oligomers (AbO) compared to PMN310 and PMN350, also displays an optimal target product profile of selective binding to toxic AbO. PMN330 was designated third validated lead product candidate having demonstrated in vivo data and biologic evidence of neuronal protection against toxic AbO.

 

·      In Q3 2017 the Company initiated its preclinical program to evaluate the potential best in class profile of PMN310, PMN350 and PMN330 in direct comparison to other antibodies targeting amyloid beta.

 

·      In Q3 the Company generated monoclonal antibodies against a recently identified epitope target on TDP43 for ALS and frontotemporal dementia and initiated preclinical evaluation.

·      Using the ProMIS proprietary discovery platform the Company is pursuing identification of specific targets on alpha synuclein (Parkinson’s disease and Lewy body dementia) and tau (Alzheimer’s disease, other dementias).

 

Financial Results

Results of Operations – Three months ended September 30, 2017 and 2016

The net loss for the three months ended September 30, 2017 was $1,618,681, compared to a net loss of $859,371 for the three months ended September 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.  

For the three months ended September 30, 2017, the Company recognized $9,008 in royalty revenue related to its preclinical AD diagnostic assay as compared to $0 for the three months ended September 30, 2016.

Research and development expenses for the three months ended September 30, 2017 were $1,317,893 as compared to $492,717 in the three months ended September 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program and increased headcount. 

General and administrative expenses for the three months ended September 30, 2017 were $307,533 as compared to $366,654 in the three months ended June 30, 2016.  The decreased expenditures in the current period reflect Foreign exchange gain on USD denominated expenses and decreased legal and professional fees, offset by higher investor relations expenses and higher salaries related to expansion of the senior management team. 

Results of Operations – Nine months ended September 30, 2017 and 2016

The net loss for the nine months ended September 30, 2017 was $4,894,280, compared to a net loss of $2,243,874 for the nine months ended June 30, 2016.  The increased loss in the current period reflects the costs associated with operating the Company’s AD therapeutics program, supporting its patent portfolio, associated general corporate expenditures and higher stock-based compensation.  

For the nine months ended September 30, 2017, the Company recognized $9,666 in royalty revenue related to its preclinical AD diagnostic assay as compared to $2,486 for the nine months ended September 30, 2016.

Research and development expenses for the nine months ended September 30, 2017 were $3,303,962 as compared to $1,169,228 in the nine months ended September 30, 2016.  Costs are higher in the current period due to higher research program costs for the AD therapeutics program, supporting its patent portfolio and increased headcount 

General and administrative expenses for the nine months ended September 30, 2017 were $1,592,881 as compared to $1,063,710 in the nine months ended September30, 2016.  The increased expenditures in the current period reflect higher investor relations expenses, higher salaries related to expansion of the senior management team, higher professional fees, and higher stock-based compensation offset by foreign exchange gain on USD denominated expense and reduced legal expenses. 

 

Outlook

The Company’s priorities for the next year are to identify and develop precision medicine therapeutics for Alzheimer’s disease (AD) and ALS.

The Company’s plan is to further advance its AD portfolio, with a focus on competitive differentiation versus other antibody therapies in development for AD that target amyloid beta. Furthermore, the Company plans to continue on-going development of effective AD diagnostics for detection of toxic prion strains targeted by ProMIS antibody therapeutic candidates in either cerebrospinal fluid or blood. Technology refinement and optimization are ongoing to create highly sensitive assays for this purpose.

The Company will continue to expand its intellectual property estate relating to novel epitope targets and antibodies targeting toxic forms of tau for AD, misfolded forms of  TDP43 for ALS and  toxic strains of alpha synuclein for Parkinson’s disease. The Company’s complementary proprietary platform technologies, ProMISTM and Collective Coordinates, will be employed to identify and confirm such novel targets.

 

About ProMIS Neurosciences, Inc.

 

ProMIS Neurosciences is a Toronto Stock Exchange (TSX) listed biotechnology company (trading symbol: PMN.TO), headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The Company’s   proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets, known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS.

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

For further information please consult the Company’s website at:

www.promisneurosciences.com

 

Follow us on Twitter
Like us on LinkedIn

 

For media inquiries, please contact:

 

Scott Santiamo
RussoPartners/LLC
[email protected]
Tel. 718 344-5843

 

David Schull

RussoPartners/LLC

[email protected]

Tel. 858 717-2310

 

For Investor Relations please contact:

 

Alpine Equity Advisors

Nicholas Rigopulos, President

[email protected]

Tel. 617 901-0785

 

 

 

Dr. Elliot Goldstein

President and Chief Executive Officer, ProMIS Neurosciences Inc.

Tel. 415 341-5783

[email protected]

 

 

 

 

 

Show more…Hide…


hjkoot3 months

hjkoot has joined the group PROMIS NEUROSCIENCES INC



Victoria Bennett3 months

Victoria Bennett has joined the group PROMIS NEUROSCIENCES INC



Kristen Galfetti3 months

Kristen Galfetti has joined the group PROMIS NEUROSCIENCES INC



No photo
Sally Woo3 months

Sally Woo has joined the group PROMIS NEUROSCIENCES INC



8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic WHY IS PROMIS NEUROSCIENCE A GOOD INVESTMENT? POINT 2. in group PROMIS NEUROSCIENCES INC

 2. Management team. Experienced, complementary management team with outstanding scientific and business advisory boards.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic Why is ProMis Neuroscience a good investment? Point 1. in group PROMIS NEUROSCIENCES INC

  1. Massive market opportunity and unmet medical need in Alzheimer’s disease. No therapies available today to stop the progression of Alzheimer’s disease (AD). Total US AD healthcare costs > $500BB, expected to triple over next 10-15 years. ProMIS product candidates are uniquely designed to selectively block the toxic strains of Amyloid beta, to stop the fundamental, underlying driver causing death of brain neurons in AD.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations posted an update in the group PROMIS NEUROSCIENCES INC

Please note the recent coverage of PMN310 by Alzheimer’s News today.

https://alzheimersnewstoday.com/2017/10/20/study-shows-that-alzheimers-therapy-pmn310-binds-only-to-toxic-amyloid-beta/

Shutterstock 256201054

Alzheimer's Therapy PMN310 Binds Only to Toxic Protein, Study Shows

Read about a study showing that ProMIS's antibody therapy PMN310 binds only with the harmful forms of amyloid beta associated with Alzheimer’s.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic Presentation by ProMIS Chief Development Officer, Dr. Johanne Kaplan, on PMN310 Best in Class Product Profile in group PROMIS NEUROSCIENCES INC

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations started the topic $PMN: News Alert Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in group PROMIS NEUROSCIENCES INC

 ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease

Narrated presentation of results available on ProMIS website

TSX: PMN

TORONTO and CAMBRIDGE, MA, Oct. 17, 2017 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that its lead product candidate for Alzheimer’s disease, PMN310, showed the desired binding profile of selectively targeting amyloid beta oligomers in a preclinical study directly comparing PMN310 to other amyloid beta-directed antibodies for Alzheimer’s disease (AD).

ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

A narrated presentation of these results is available on the ProMIS Neurosciences website at: http://bit.ly/2gp8S4t

Commenting on these results, ProMIS President and CEO, Elliot Goldstein, MD, stated: “We are pleased to confirm the selective binding of PMN310 to amyloid beta oligomers, a root cause of Alzheimer’s disease. Results of prior clinical studies with other amyloid beta antibody therapeutics clearly showed that antibodies targeting amyloid beta monomer have consistently been ineffective, while those targeting amyloid beta fibrils, the main component of plaque, are associated with a dose limiting toxicity of brain swelling. Taken together, results of prior clinical trials indicate the best in class target product profile is selective binding of toxic amyloid beta oligomers.”

The binding profile of PMN310 was compared to that of other candidate antibody therapeutics for AD in a preclinical study using the “dot blot” technique. Results of the study showed that PMN310 selectively binds amyloid beta oligomers (AbO), with virtually no binding to the other forms of amyloid beta. By comparison, solanezumab (Eli Lilly) showed binding mainly to Ab monomers; bapineuzumab (Johnson & Johnson/Pfizer, discontinued) showed binding to all forms of Ab (monomers, fibrils, oligomers); and aducanumab (Biogen) showed preferential binding to fibrils and oligomers.

Dot blotting is a method of applying (dotting) proteins, such as Ab monomers, fibrils and oligomers, directly onto a membrane or other support. Samples of the antibody to be evaluated are then applied and the binding pattern to the various forms of amyloid beta can be observed.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company’s website at: 
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

 

SOURCE ProMIS Neurosciences Inc.

Show more…Hide…


8020 media relations
Media Relations3 months
Disclaimer

Media Relations posted an update in the group PROMIS NEUROSCIENCES INC

Narrated Corporate Overview October 2017

Show more…Hide…


Elliot Goldstein4 months

Elliot Goldstein has joined the group PROMIS NEUROSCIENCES INC



Darren Stewart4 months
Disclaimer

Darren Stewart posted an update in the group PROMIS NEUROSCIENCES INC

I want to bring your attention to a new tool we added in September, the "New User" invite tool. It's very simple, just add the email of a person you think would be an interested investor or could add value to the corporation. Click on the "SEND INVITES" button above to find the New User tool. (The image below should help). As shareholders, we now have the ability to be more than passive investors, we can be active owners helping our investments succeed. Darren Stewart, CEO and founder of 8020 Connect.

Show more…Hide…


Yousuf Soliman4 months

Yousuf Soliman has joined the group PROMIS NEUROSCIENCES INC



8020 media relations
Media Relations4 months
Disclaimer

Media Relations started the topic $PMN News Alert: ProMIS Neurosciences Provides Third Quarter Update for 2017 in group PROMIS NEUROSCIENCES INC

ProMIS Neurosciences Provides Third Quarter Update for 2017

Updated corporate overview available on ProMIS website

TSX: PMN

TORONTO and CAMBRIDGE, MA, Oct. 11, 2017 /PRNewswire/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today provided a corporate update for the third quarter of 2017, including key accomplishments and a status update on ongoing programs.

A narrated corporate overview of third quarter 2017 progress is available on the ProMIS Neurosciences website at: http://bit.ly/2xuss6Q

 Key accomplishments in the third quarter of 2017 and near-term value drivers include:

  • Closed second and final tranche of private placement, raising aggregate gross proceeds of approximately CDN $4,800,000
  • Successful humanization of lead product candidate PMN310 for Alzheimer’s disease 
    • PMN310 on track for 2019 initiation of clinical trials
  • Expansion of potential best in class portfolio selectively targeting toxic Amyloid beta oligomers (AβO) for Alzheimer’s disease
    • Designated PMN330 as third validated lead product candidate demonstrating in vivo data and biologic evidence of neuronal protection against toxic AβO
    • Initiated humanization of PMN330 and PMN350
  • Preclinical program initiated to confirm best in class profile of PMN310, PMN350 and PMN330 in direct comparison to other antibodies targeting amyloid beta
  • Cohort study progress
    • Technology refinement and optimization ongoing to create highly sensitive assays for detection of AβO targets in cerebrospinal fluid (CSF)
  • Recognition and visibility at major international meetings
    • Oral presentation and session chair at Alzheimer’s Association International Conference, London, UK, July, 2017
    • Oral presentation at Third Annual R&D Technologies Conference, London, UK, September, 2017
  • Progress relating to multiple neurodegenerative diseases
    • Generated monoclonal antibodies against a recently identified epitope target on TDP43 for ALS and frontotemporal dementia and initiated preclinical evaluation.
    • Ongoing work using ProMIS proprietary discovery platform to identify specific targets on alpha synuclein (Parkinson’s disease and Lewy body dementia) and tau (Alzheimer’s disease, other dementias)

 

Commenting on the update, ProMIS Executive Chairman Eugene Williams stated: “Our Alzheimer’s disease program continues to make significant progress. With respect to drug development, our priorities for this program are twofold: to drive PMN310 to clinical trial initiation in 2019 and importantly, to further differentiate our Alzheimer’s product candidates as best in class in direct comparison to other antibody treatments targeting Amyloid beta. With respect to our research programs, we are pleased with the progress made using our proprietary discovery engine to identify novel targets for multiple neurodegenerative diseases.”

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a Toronto Stock Exchange listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario with offices in Cambridge, Massachusetts. The Company’s mission is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and ALS.

ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique “precision medicine” approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer’s disease and ALS.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Show more…Hide…


LauraGaret4 months
Disclaimer

LauraGaret posted an update in the group PROMIS NEUROSCIENCES INC

https://www.wired.com/story/polygenic-alzheimers-test-predicts-age-of-disease-onset/

Alzheimers fa

This New Alzheimer’s Test Looks Beyond a Single Problem Gene

It calculates how more than two dozen genetic variants combine to increase or decrease your risk of developing Alzheimer's during your lifetime.

Show more…Hide…


Interested in ICOS?
ICOxConnect
Start Investing